Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

Hair regrowth was achieved using minoxidil, nizoral, alfatrodial, and pyrilutamide after finasteride caused side effects. The user recommends this combination for those who can't tolerate 5AR inhibitors, stressing consistent use.

Users discussed using pyrilutamide from Minoxidilmax for hair loss, with some reporting reduced shedding and anti-androgenic side effects like reduced sex drive. Dosages varied, with some using 2.5mg or 5mg daily, and costs were noted as a concern.

A 34-year-old man is using natural methods like rosemary and peppermint oil, micro-needling, and low-level laser therapy to manage hair thinning, avoiding medications like minoxidil and finasteride. Despite minimal visible progress, he values the non-medicated approach and remains consistent with his routine.

The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.

The user plans to aggressively treat hair loss by using 1.25mg finasteride daily, 1mL minoxidil twice daily, and topical dutasteride with microneedling weekly, despite experiencing side effects from finasteride previously. They intend to switch to a maintenance routine with topical minoxidil and dutasteride after regaining hair.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

OP is considering adding topical bimatoprost or latanoprost to their hair loss treatment, which already includes oral minoxidil, and is seeking reliable sources for these products. Users discuss the effectiveness and sourcing of these treatments, with some using bimatoprost for both hairline and eyelashes, and others planning to use latanoprost mixed with finasteride.

A user shared their positive experience with a 2800-graft hair transplant in Patna, emphasizing the importance of choosing an experienced surgeon over flashy clinics. Despite mixed reactions, the user is satisfied with the natural results and increased confidence.

The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

A 25-year-old with aggressive diffuse NW5 hair loss is using Minoxidil, oral Finasteride, RU58841, Ketoconazole, and dermastamping, experiencing slow progress and mental health struggles. Despite some visible regrowth, the user feels discouraged due to ongoing hair loss and is seeking reassurance and advice.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.

The conversation discusses the effectiveness of official and gray market Pyrilutamide for hair loss. One user experienced chest pain with the gray market version, while another found the official Koshine version mildly effective.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

RU58841 is considered ineffective as a standalone treatment for hair loss, with users often combining it with finasteride and minoxidil for potential benefits. Many users report mixed results and concerns about side effects, leading to skepticism about its efficacy.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

A 21-year-old is concerned about whether their hairline is a normal mature hairline or indicates male pattern baldness, despite no family history of baldness. They plan to provide clearer pictures for better assessment.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.